Lipigon Pharmaceuticals

Mindre end 1K følgere

Oversigt

Investorkonsensus

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse3.12.2025, 17.55

Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels

Lipigon Pharmaceuticals

Pressemeddelelse21.11.2025, 11.19

Redeye: Lipigon (Q3 Review) - Topline Before Year-End

Lipigon Pharmaceuticals

Pressemeddelelse14.10.2025, 20.58

Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense

Lipigon Pharmaceuticals

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse26.8.2025, 12.28

Redeye: Lipigon Q2 2025 - Last Patient In

Lipigon Pharmaceuticals

Selskabsmeddelelse6.7.2025, 07.03

Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®

Lipigon Pharmaceuticals

Pressemeddelelse27.5.2025, 06.36

Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue

Lipigon Pharmaceuticals

Pressemeddelelse31.3.2025, 06.25

Redeye: Lipigon Q4 2024 - Rights issue funds 2025

Lipigon Pharmaceuticals

Selskabsmeddelelse20.3.2025, 11.15

Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense

Lipigon Pharmaceuticals

Pressemeddelelse21.11.2024, 13.12

Redeye: Lipigon Q3 2024 - First Patient Recruited

Lipigon Pharmaceuticals

Selskabsmeddelelse21.11.2024, 09.00

Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®

Lipigon Pharmaceuticals

Pressemeddelelse18.9.2024, 10.51

Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®

Lipigon Pharmaceuticals

Pressemeddelelse28.8.2024, 05.43

Redeye: Lipigon Q2 2024 - Marea Launched

Lipigon Pharmaceuticals

Selskabsmeddelelse9.7.2024, 12.00

Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study

Lipigon Pharmaceuticals

Pressemeddelelse20.6.2024, 06.30

New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes

Lipigon Pharmaceuticals

Pressemeddelelse29.5.2024, 06.03

Redeye: Lipigon Q1 2024 - Phase II Underway

Lipigon Pharmaceuticals

Pressemeddelelse15.5.2024, 06.28

Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress

Lipigon Pharmaceuticals

Selskabsmeddelelse14.5.2024, 05.53

Lipigon collaborates with University of Washington on lung damage project

Lipigon Pharmaceuticals

Pressemeddelelse23.2.2024, 07.08

Redeye: Lipigon Q4 2023 - Phase II study approved

Lipigon Pharmaceuticals

Pressemeddelelse7.2.2024, 15.00

The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®

Lipigon Pharmaceuticals

Pressemeddelelse12.12.2023, 09.11

Lipisense® progressing to Phase II - what comes next?

Lipigon Pharmaceuticals

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.